Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

After 6 months, the calcitriol group showed lower increases in IL-6 levels (baseline 0.72 pg/mL to 0.87 pg/mL) compared to placebo (1.03 pg/mL to 2.94 pg/mL, p = 0.006), and lower KIM-1 levels (0.36 to 0.51 ng/mL vs. 0.55 to 0.99 ng/mL, p = 0.020).

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Randomised controlled trial.

Randomised controlled trial

Assigns participants or groups to comparison interventions by chance.

Meta-analysis unclear · Double-blind reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Modulation of renal inflammation and tubular injury by calcitriol in patients with early diabetic kidney disease: a randomized controlled trial

Source: Article title.

This double-blind, randomized controlled trial (RCT) was conducted at the Cipto Mangunkusumo and Pelni Hospitals in Jakarta, Indonesia, from July 22nd, 2022 to August 11th 2023.

Source: Methods.

Participants were randomly assigned to two equal groups (60 each) using SPSS® version 25.0 (IBM Corp., Armonk, NY, USA).

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Modulation of renal inflammation and tubular injury by calcitriol in patients with early diabetic kidney disease: a randomized controlled trial

Randomised controlled trial · Annals of Medicine · 2025

Original publication title

Modulation of renal inflammation and tubular injury by calcitriol in patients with early diabetic kidney disease: a randomized controlled trial

Pringgodigdo Nugroho; Aida Lydia; Pradana Soewondo; Suhardjono; Ina Susianti Timan; Kuntjoro Harimurti; Zulkhair Ali

© 2025 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

These findings suggest that Calcitriol supplementation may provide renoprotection in patients with early DKD by reducing inflammation and tubular injury, with potential effects on podocyte injury. Further research is required to validate these effects and determine the optimal dosing regimens.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Diabetic kidney disease (DKD) is marked by inflammation, fibrosis and oxidative stress. Calcitriol may offer renoprotective effects by modulating these processes. This double-blind, randomized controlled trial investigated the effects of calcitriol supplementation on kidney injury biomarkers in patients with early DKD.

Source: Introduction

Abstract: What methods does the paper describe?

This study randomized 120 patients with controlled type 2 diabetes, albuminuria, and estimated glomerular filtration rate above 45 mL/min/1.73 m2 to receive either 0.25 mcg/d calcitriol or a placebo for six months. The primary outcomes were changes in urinary nephrin, podocin, kidney injury molecule-1 (KIM-1), interleukin-6 (IL-6), and urinary albumin-to-creatinine ratio (UACR).

Source: Patients and methods

Abstract: Results

After 6 months, the calcitriol group showed lower increases in IL-6 levels (baseline 0.72 pg/mL to 0.87 pg/mL) compared to placebo (1.03 pg/mL to 2.94 pg/mL, p = 0.006), and lower KIM-1 levels (0.36 to 0.51 ng/mL vs. 0.55 to 0.99 ng/mL, p = 0.020). Full baseline and post-treatment values are provided in Tables 2. Urinary nephrin levels decreased in the calcitriol group, while change in the placebo group varied. Although UACR decreased more in the calcitriol group, the difference was not statistically significant (p = 0.099).

Positive correlations were observed between KIM-1 and IL-6 in both groups, and a moderate correlation between IL-6 and urinary nephrin was observed in in the calcitriol group. No significant adverse events or changes in serum calcium or phosphate levels were reported.

Source: Results

Abstract: Conclusion

These findings suggest that Calcitriol supplementation may provide renoprotection in patients with early DKD by reducing inflammation and tubular injury, with potential effects on podocyte injury. Further research is required to validate these effects and determine the optimal dosing regimens.

Source: Conclusion
Authors’ abstract

Abstract

Introduction

Diabetic kidney disease (DKD) is marked by inflammation, fibrosis and oxidative stress. Calcitriol may offer renoprotective effects by modulating these processes. This double-blind, randomized controlled trial investigated the effects of calcitriol supplementation on kidney injury biomarkers in patients with early DKD.

Patients and methods

This study randomized 120 patients with controlled type 2 diabetes, albuminuria, and estimated glomerular filtration rate above 45 mL/min/1.73 m2 to receive either 0.25 mcg/d calcitriol or a placebo for six months. The primary outcomes were changes in urinary nephrin, podocin, kidney injury molecule-1 (KIM-1), interleukin-6 (IL-6), and urinary albumin-to-creatinine ratio (UACR).

Results

After 6 months, the calcitriol group showed lower increases in IL-6 levels (baseline 0.72 pg/mL to 0.87 pg/mL) compared to placebo (1.03 pg/mL to 2.94 pg/mL, p = 0.006), and lower KIM-1 levels (0.36 to 0.51 ng/mL vs. 0.55 to 0.99 ng/mL, p = 0.020). Full baseline and post-treatment values are provided in Tables 2. Urinary nephrin levels decreased in the calcitriol group, while change in the placebo group varied. Although UACR decreased more in the calcitriol group, the difference was not statistically significant (p = 0.099).

Positive correlations were observed between KIM-1 and IL-6 in both groups, and a moderate correlation between IL-6 and urinary nephrin was observed in in the calcitriol group. No significant adverse events or changes in serum calcium or phosphate levels were reported.

Conclusion

These findings suggest that Calcitriol supplementation may provide renoprotection in patients with early DKD by reducing inflammation and tubular injury, with potential effects on podocyte injury. Further research is required to validate these effects and determine the optimal dosing regimens.

Trial registration

ClinicalTrials.gov (NCT05298163).

Key messages

  1. The administration of 0.25 mcg/d calcitriol for 6 months was safe and well tolerated, supporting its potential clinical applicability.

  2. The protective effects of calcitriol in patients with early-stage DKD was primarily mediated through its anti-inflammatory properties, as evidenced by the significant reduction in urinary IL-6 and KIM-1 levels. The strong correlation between changes in IL-6 and KIM-1 further supports the anti-inflammatory property of calcitriol as a key mechanism underlying its renoprotective action.

  3. However, the effects of calcitriol on podocyte injury and albuminuria are limited. This suggests that the benefits of 0.25 mcg/d calcitriol for 6 months benefits in patients with early DKD do not extend to direct podocyte protection.

Publication and source details

Original title: Modulation of renal inflammation and tubular injury by calcitriol in patients with early diabetic kidney disease: a randomized controlled trial

Pringgodigdo Nugroho; Aida Lydia; Pradana Soewondo; Suhardjono; Ina Susianti Timan; Kuntjoro Harimurti; Zulkhair Ali

Annals of Medicine · 2025

Supplemental data for this article can be accessed online at https://doi.org/10.1080/07853890.2025.2577271.

CONTACT Pringgodigdo Nugroho pringgodigdo.nugroho@ui.ac.id Division of Nephrology and Hypertension, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia: Dr. Cipto Mangunkusumo Hospital Jl. Diponegoro no. 71, Jakarta10430, Indonesia.
© 2025 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group2025The Author(s)https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T00:42:50.418665+00:00

DOI: 10.1080/07853890.2025.2577271 · PMC12570221